You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖-B(02696.HK)就注射用曲妥珠單抗與Accord訂立許可協議修正案
格隆匯 06-24 19:14

格隆匯6月24日丨復宏漢霖-B(02696.HK)發佈公告,於2020年6月24日,公司就HLX02(注射用曲妥珠單抗)與Accord Healthcare Limited訂立《許可協議修正案》,協議修正案在雙方於2018年6月就HLX02訂立的《許可協議》基礎上,就HLX02新增規格及對應里程碑付款安排、許可使用費調整等作出約定。

在原合作協議授權許可的150mg規格的HLX02基礎上,新增授權許可60mg、420mg規格的HLX02。Accord將根據HLX02新增規格的上市申請進度、藥品交付進度向本公司支付里程碑款項合計不超過308萬美元(包括新增規格HLX02的製劑開發及工藝驗證批次成本),相關費用均應於相關事件發生後的45日內支付。

Accord應在協議約定期限內,根據HLX02在許可區域內的淨銷售額達成情況向公司支付許可使用費。許可使用費的分成比例區間將從原合作協議約定的淨銷售額產生利潤的13.5%-25%,提升至15%-26.5%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account